Significant investments and technological advances are driving shifts in biomanufacturing. AbbVie announced a $195 million expansion of its North Chicago active pharmaceutical ingredient (API) facility to support production of neuroscience, immunology, and oncology medicines, underpinning a $10 billion domestic investment commitment. Meanwhile, Washington University secured up to $5.2 million federal funding to enhance sustainable biomanufacturing approaches using engineered microbes. Advances in adeno-associated virus vector production and accelerated DNA plasmid manufacturing promise to meet rising gene and cell therapy demands with improved efficiency and scalability.